Title
Inhibition of the norepinephrine transporter improves behavioral flexibility in rats and monkeys.

Permalink
https://escholarship.org/uc/item/2jb4x6gh

Journal
Psychopharmacology, 202(1-3)

ISSN
0033-3158

Authors
Seu, Emanuele
Lang, Andrew
Rivera, Ronald J
et al.

Publication Date
2009

DOI
10.1007/s00213-008-1250-4

Peer reviewed
Inhibition of the norepinephrine transporter improves behavioral flexibility in rats and monkeys

Emanuele Seu · Andrew Lang · Ronald J. Rivera · J. David Jentsch

Received: 20 April 2008 / Accepted: 22 June 2008 / Published online: 7 July 2008 © The Author(s) 2008

Abstract

Rationale Poor cognitive control, including reversal learning deficits, has been reported in children with attention deficit hyperactivity disorder, in stimulant-dependent humans, and in animal models of these disorders; these conditions have each been associated with abnormal catecholaminergic function within the prefrontal cortex.

Objectives In the current studies, we sought to explore how elevations in extracellular catecholamine levels, produced by pharmacological inhibition of catecholamine reuptake proteins, affect behavioral flexibility in rats and monkeys.

Materials and methods Adult male Long–Evans rats and vervet monkeys were trained, respectively, on a four-position discrimination task or a three-choice visual discrimination task. Following systemic administration of pharmacological inhibitors of the dopamine and/or norepinephrine membrane transporters, rats and monkeys were exposed to retention or reversal of acquired discriminations.

Results In accordance with our a priori hypothesis, we found that drugs that inhibit norepinephrine transporters, such as methylphenidate, atomoxetine, and desipramine, improved reversal performance in rats and monkeys; this was mainly due to a decrease in the number of perseverative errors. Interestingly, the mixed dopamine and norepinephrine transporters inhibitor methylphenidate, if anything, impaired performance during retention in both rats and monkeys, while administration of the selective dopamine transporter inhibitor GBR-12909 increased premature responses but did not alter reversal learning performance.

Conclusions Our results suggest that pharmacological inhibition of the membrane norepinephrine, but not membrane dopamine, transporter is associated with enhanced behavioral flexibility. These data, combined with earlier reports, may indicate that enhanced extracellular catecholamine levels in cortical regions, secondary to norepinephrine reuptake inhibition, improves multiple aspects of inhibitory control over responding in rats and monkeys.

Keywords ADHD · Norepinephrine · Cognition · Dopamine · Reversal learning · Frontal cortex · Catecholamine

Introduction

In higher mammals, prefrontal-cortex-dependent executive functions support behavioral adaptation to a changing environment by permitting the introduction of flexibility into responding. Without this top-down cognitive control, behavior is more likely to be driven by simple sensory motor associations and habits (depending upon other cortical and subcortical regions), resulting in automatic and/or inflexible behavior (Miller and Cohen 2001).

Laboratory tasks, such as discrimination reversal learning, have been used in both human and animal subjects to study aspects of executive control and behavioral flexibility (Ragozzino 2007; Robbins 2007; Roberts and Wallis 2000). In related procedures, the associations between stimuli and outcomes are learnt by a subject before being unexpectedly
reversed by the experimenter; after reversal, subjects have to alter their behavioral repertoire in order to discover the predictors of reward and/or to avoid a punishment. This may require the subject to stop pre-potent or conditioned responses (i.e., response inhibition) and/or overcome the learned irrelevance for the alternative responses (Clarke et al. 2007; Tait and Brown 2007), while the generation of new behaviors may arise by the intervention of others executive processes, such as working memory and/or response selection (Frank and Claus 2006; Miller and Cohen 2001).

Previous studies have shown that damage to the orbitofrontal cortex produces a selective reversal learning deficit (Boulougouris et al. 2007; Dias et al. 1996; Hornak et al. 2004; Iversen and Mishkin 1970; McAlonan and Brown 2003; Rolls et al. 1994; Schoenbaum et al. 2002), along with poor response inhibition (Aron et al. 2003b; Eagle et al. 2008), while damage to other prefrontal regions impairs behavioral flexibility only when the updating of attentional biases or rules is required (Birrell and Brown 2003; Rolls et al. 1994; Schoenbaum et al. 2002), suggesting that the inhibition of the NET alone may improve cognitive control.

In the current study, we compared the actions of drugs selective for each of the two catecholamine transporters, with MPH, in reversal learning tasks designed to measure aspect of cognitive control and flexible responding in rodents and non-human primates. We exposed rats to serial retentions and reversals of a four-choice spatial discrimination task, and we tested the effect of the administration of the stimulant drug MPH, the selective DAT inhibitor GBR-12909 (GBR), and the selective NET inhibitors ATO and desipramine (DMI). Monkeys performing a three-choice discrimination task that included two different sets of visual discriminanda were also used to examine the effects of a subset of these agents. We predicted that by virtue of NET inhibition, MPH, ATO, and DMI would improve performance selectively under reversal condition, while GBR would not. By employing three- and four-choice tasks in monkeys and rats, respectively, we were able to examine the patterns of errors made by subjects in order to dissociate perseverative errors (i.e., responses to the previous rewarded hole) from neutral errors (i.e., responses to the other incorrect holes), clarifying whether changes in reversal learning performance could be attributed to the ability to change the initially trained response (i.e., response inhibition).

Materials and methods

Subjects

Sixty-one adult male Long-Evans rats (Harlan, Indianapolis, IN, USA) were used in these experiments. The subjects were ~60 days of age at the initiation of training and ranged in weight from 300 to 400 g during the experimental period. All rats were initially food-restricted
to 80–85% of their free-feeding weights and subsequently fed ~15 g rat chow per day in their home cage within 1–3 h after testing. Water was continuously available, except while in the operant testing chambers. Rats were maintained in a 14/10-h light/dark schedule (lights on at 7 A.M.).

In addition, four male vervet monkeys (Chlorocebus aethiops sabaeus) from the UCLA Vervet Research Colony were included in the experiments; they were 9–11 years of age and weighed 6.0–8.0 kg at the time of testing. The monkeys were housed individually in a climate-controlled vivarium on a 12-h light/dark cycle (lights on at 6 A.M.); they had unlimited access to water and received a nutritionally balanced diet of monkey chow (Teklad, Madison WI, USA) supplemented with fresh fruit. The monkeys received their full daily allotment of food (which was not reduced in order to support behavioral performance) immediately after morning testing (one half portion) and again at 1600–1700 hours (one half portion).

The experimental protocols employed were consistent with the NIH “Guide for the Care and Use of Laboratory Animals” and were approved by the Chancellor’s Animal Research Committee at UCLA. All methods for the care and use of nonhuman primates conformed to US Department of Agriculture and Public Health Service standards.

Drugs

For the rat studies, doses of atomoxetine hydrochloride (1.0 mg/kg, gift from Pfizer) and desipramine hydrochloride (5.0 mg/kg; Sigma-Aldrich; St Louis, MO, USA) were chosen based upon previous studies showing relevant effects of these drugs in other behavioral procedures that measure inhibitory control in rats (Eagle et al. 2007; van Gaalen et al. 2006a).

All drugs were dissolved in sterile saline (0.9%) and were administered in a volume of 1.0 ml/kg, with the exception of GBR-12909 that was administered in a volume of 2.0 ml/kg. Methylphenidate, GBR-12909, and desipramine were injected 30 min before testing, while atomoxetine was administered 45 min prior to testing.

For the monkey studies, doses of atomoxetine (1 mg/kg; Tocris-Cookson; Elllisville, MO, USA) and methylphenidate (0.33 mg/kg; Sigma-Aldrich) were selected on the basis of pilot studies in which two different doses were tested on the same subjects but using a slightly different reversal learning task. We chose to administer all drugs by oral delivery rather than via intramuscular injections for the reason that we expected such route of administration to be better comparable with clinical studies. Drugs were mixed with fruit jam or peanut butter and put in a small cookie. Before every acquisition session, a cookie with jam or peanut butter (but without drug) was given to the subjects to avoid the fact that the cookie might be recognized as cue for the subsequent retention or reversal session. Drugs were administered 1 h before the retention or reversal sessions, and the experimenter assured whether the cookie and jam were eaten or not.

Rat behavioral testing apparatus

Standard extra-tall aluminum and Plexiglas operant conditioning chambers with a photocell-equipped pellet delivery magazine on one side and a curved panel with five photocell-equipped apertures on the opposite side (Med Associates, Mount Vernon, VT, USA) were used. The boxes were housed inside a sound-attenuating cubicle, background white noise was broadcasted, and the environment was illuminated with a houselight (a light diffuser that was located outside of the operant chamber but within the cubicle).

Rat training

Most of the prior reversal learning studies described in rodents and monkeys have been conducted using two-choice discrimination tasks (Boulougouris et al. 2007; Dias et al. 1996; Iversen and Mishkin 1970; McAlonan and Brown 2003; Schoenbaum et al. 2002). We chose to adopt a novel four-choice task in order to increase general task difficulty and to permit us to dissect perseverative from neutral errors.

The procedure for the initial training was similar to that used for a lateralized reaction time task (Jentsch 2003). Rats were first trained in a single session in which the houselight was continuously illuminated and single pellets (45 mg Dustless Precision Pellets; Bio-serv, Frenchtown, NJ, USA) were delivered into an illuminated magazine on a fixed-time 20-s schedule over a 45-min period. Across three subsequent daily sessions, the rats were then trained to make a sustained, variable duration nose poke (200, 500, 700, or 1,000 ms) in an illuminated center nose poke aperture (hole 3) to receive a pellet. This response (called the observing response) was used in the subsequent sessions to begin a new trial in order to demonstrate task engagement and to avoid random responding. All rats were trained until they earned at least 70–80 pellets in this initial shaping component.

The rats were then tested in daily discrimination sessions in which the initiation of individual trials was signaled by the illumination of the central aperture. A variable-duration observing response at that location resulted in the immediate switching off of the central light and illumination of
the four remaining apertures, two to the left of the central aperture (holes 1 and 2; H1 and H2) and two to the right (holes 4 and 5; H4 and H5). On any given day, one of the holes was chosen by the experimenter to be the target hole, and rats were reinforced with a pellet for a response into that hole only (correct response). Importantly, no signal, other than reinforcement feedback, indicated which of the four holes was the target on any given day.

If the rat responded at a location that was not the established target, all lights in the box were extinguished, and the rat was given a 3-s time-out period in complete darkness (incorrect response). If no response was made within 15 s, the rat received a 3-s time-out in darkness (omission). The inter-trial interval that followed a completed trial or omission was 3 s. On occasion, rats responded into one of the lateral apertures before completing the sustained nose poke (and before the target presentation); in this case, a 3-s time-out was delivered (as above), and an anticipatory response was scored.

Sessions were terminated when rats reached criteria of 18 correct responses in 20 consecutive trials, after 1 h or when 200 trials were completed, whichever came first. If rats failed to achieve criterion performance in 1 h or 200 trials, the discrimination was repeated on subsequent days until criterion was met.

The subjects were exposed to approximately 1 month of initial training. During this time, rats were tested every 2 to 4 days for an average of 12 discrimination sessions (including one to two retention sessions), with each of the four holes assigned as target locations at least twice.

Rat testing—experimental design

After initial training, rats were tested for 2 days a week in pairs of experimental sessions. During the first session, referred to as the “new-hole session”, an aperture was selected pseudorandomly. In the second session, rats were tested for “retention” of the discrimination learned in the prior new-hole session (the reinforcement rule was kept the same) or they were subjected to a “reversal” of the discrimination learned in the prior new-hole session (a different aperture was rewarded). Pharmacological treatments were administered only during retention or reversal sessions, while the new-hole sessions were always performed drug-free.

Note that the new-hole sessions may be considered a reversal session because the rats are experiencing a change in the condition learned in the previous session. The new-hole sessions were used because it seemed to be important to always test retention or reversal of a discrimination learned in a drug-free state. This allowed us to ensure that there were no differences amongst the various drug and reversal vs. retention conditions in terms of performance in the immediately preceding session. In addition, a difference between new-hole and reversal sessions was that more restrictions were imposed in the choice of the target hole during reversal sessions in order to simplify the design and assure all the conditions within and between drug studies were balanced. For example, only a switch from holes positioned on different sides of the central hole (H5–H1, H5–H2, H4–H2, or H4–H1 and vice versa) was allowed, while this was not a requirement for new-hole sessions.

If in a drug study a rat failed to reach performance criteria in one or more drug sessions, these sessions were repeated after completion of the formal Latin square design. However, only one to three rats in each of the drug studies ever failed to complete a session, and the frequency of failures never differed between treatment groups.

All rats required at least eight to 12 discrimination sessions (including retention, reversal, and new-hole sessions) to complete each pharmacological study; considering initial training and pharmacological testing, each subject was exposed to 20–40 sessions over the course of the procedures described in this manuscript.

A minimum of four and a maximum of 14 drug administrations (of which two to four were saline administrations) were given to each rat, with an interval between injections of at least 1 week.

The measures collected during daily sessions included total number of trials (number of trials required to reach criterion), the mean trial initiation latency (the average interval between illumination of the central aperture and the initiation of the observing response), the mean pellet retrieval time (the average interval between pellet delivery and head entry into the magazine), and the number of anticipatory responses (calculated as a fraction of completed trials). Omissions were very rare and all drugs tested failed to affect them, so omissions are not presented here.

Correct and incorrect responses were measured as percentage of all completed trials in five-trial bins (trials 1–5, 6–10, etc.). In each study, we analyzed these measures across the maximum number of trials bins where data points were present for all rats (because the number of trials available for analysis depended upon how quickly the rat reached criteria). For the retention sessions, only four bins were considered in all drug studies (all experiments included rats that completed the retention sessions in the minimum number of trials, i.e., 20), while for the reversal sessions, the number of bins was variable (between four and seven).

Furthermore, incorrect responses were defined as perseverative (i.e., responses to the hole rewarded in the previous new-hole session) or neutral (responses to the other two incorrect holes) and were analyzed as a
percentage of all completed trials in five-trial bins, as described above.

Monkey behavioral testing apparatus

A modified Wisconsin general test apparatus (WGTA) consisting of an opaque screen (that could be raised and lowered) that separated the monkey from a tray fitted with three opaque square food boxes with hinged opaque lids was used. The tops of the food boxes were fitted with distinctive colored pictures (clip art from the Microsoft Office library), and the monkeys were trained to open the lids of food boxes to retrieve food rewards (bits of apple, grape, or banana) hidden within. The monkeys, which had previously been trained to move voluntarily from their cages to a transport cart, were moved, one at a time, to an adjacent testing room. In this room, the transport cart was aligned to the WGTA so that monkeys could easily access the food boxes on the tray when the opaque screen was raised. The monkeys were presented with trials on which the screen was raised to reveal three food boxes with the visual cues. They were allowed to open only one box lid per trial. Each trial lasted either until the animal opened a lid or 2 min passed, whichever came first. The inter-trial interval was approximately 15 s. For each set of three visual cues, the picture that was chosen to be the "positive" stimulus was varied across the four subjects. The position of the food boxes varied pseudorandomly across all trials. Each subject was tested between 8:30 and 11:00 A.M. on each day.

Monkey testing—reversal learning task

Before the four monkeys participated in this study, they were trained on a slightly different reversal learning paradigm and were involved in other pharmacological studies (Lee et al. 2007). We modified our earlier task design in an attempt to increase the general difficulty of the task. Our procedure, like some human discrimination learning tasks (Frank et al. 2007), involved training subjects on two separate discriminations, composed of three stimuli each, within single sessions (discrimination set 1: A,B,C; discrimination set 2: D,E,F). In every session, half of the trials included discrimination set 1 and the other half involved discrimination set 2. The two sets of stimuli were mixed pseudorandomly across trials; the only constraint on stimuli presentation order was that the same triad of pictures was not presented in more than three consecutive trials. Across daily sessions of 30 trials (15 trials with stimuli A,B,C and 15 with D,E,F), the monkeys had first to learn that one stimulus per discrimination was associated with reward while the others were not (i.e., A+, B−, C− and D+, E−, F−). Once a minimum criterion of 13 correct responses out of 15 trials was reached for both sets of stimuli in a single session, the subjects were tested on the subsequent day for retention or reversal of the two discriminations.

The maximum number of acquisition sessions allowed was four, and when a monkey did not meet this criterion in four sessions, the testing for that subject was interrupted and restarted the following week with new sets of stimuli. However, this circumstance was not very common, and often, monkeys learned both discriminations within one session.

The retention and reversal sessions consisted of two contiguous blocks of 20 trials each consisting of an equal mix of 10 A-B-C trials and ten D-E-F trials (Fig. 1). In the retention sessions, the reward contingencies in the two blocks were the same as in the acquisition sessions (A+, B−, C− and D+, E−, F−). Differently, in the reversal sessions, the stimulus—reward associations were changed so that discrimination set 1 was reversed from the beginning of the test session (A−, B+, C−), while discrimination set 2 was retained in the first block (D+, E−, F−) and reversed in the second block (D−, E+, F−). In this way, monkeys were subjected to two different reversal conditions in the session, one preceded by a retention test to “prime” responding (involving discrimination set 2) and one that was not
(involving discrimination set 1). The retention and reversal sessions were alternated in a pseudorandom way so that no more than two consecutive weeks included the same learning conditions.

The measures collected were retention session errors (total errors committed in the retention sessions), reversal session retention errors (errors committed during retention of discrimination set 2 in the first block of the reversal session), perseverative errors (number of responses to the previously reinforced stimulus during reversal of discrimination set 1 or 2), neutral errors (number of non perseverative errors during reversal session), retention session duration (total time required to complete the retention session; in s), and reversal session duration (total time required to complete the reversal session; in s).

Data analysis

All studies were within subjects and the order of drug conditions counter-balanced (cyclic Latin square design) across subjects and testing conditions (retention and reversal).

For the rat experiments, the measures described above were subjected to repeated measures analysis of variance (ANOVA), with testing condition, bin, and dose as factors. Where significant main effects or interactions were detected, they were further analyzed using a paired two-tailed t tests. Our a priori hypotheses were tested using paired one-tailed t tests.

For the monkey studies, specific a priori hypotheses were examined using one-tailed paired t tests, while for all the other comparisons, two-tailed paired t tests were used.

Results

Rat studies: baseline performance characteristics

The data collected under saline-only conditions in all the rat experiments are summarized in Fig. 2 in order to exhibit baseline performance characteristics of rats performing the four-choice discrimination task. In retention, rats perform at ~50% accuracy within the first five trials of the session (chance performance=25%), reaching ~80% accuracy by trials 16–20, while under the reversal condition, rats start out with accuracy which is below chance (Fig. 2a), mainly due to a tendency to respond toward the previously rewarded hole (Fig. 2b). Indeed, nearly 50% of the total responses emitted in the first four bins of the reversal phase were perseverative (Fig. 2b). Together with this observation, the analysis of responses to the two “neutral” holes revealed that performance was guided by a set of long-term reinforcement rules, incorporating information learned over many sessions; in fact, rats responded more to the neutral hole that was rewarded in the most recent session (i.e., recent neutral) than to the neutral hole reinforced longest in the past (i.e., past neutral; Fig. 2b). When considering accuracy of response during the first four five-trial bins, ANOVA detected a significant interaction between testing condition (retention versus reversal) and trial bin \([F(1,80)=F_{(1,80)}=3.0, p\leq0.05]\), along with main effects of testing condition \([F(1,80)=228.6, p\leq0.0001]\) and trial bin \([F(1,80)=26.7, p\leq0.0001]\). A main effect of testing condition was also observed in the total number of trials required to reach criterion \([F(1,80)=142.1, p\leq0.0001]\) (data not shown).

We ran several analyses in order to evaluate whether there were differences in the difficulty of performance in reversal depending upon which hole was being reinforced in the test session and which hole had been reinforced in the previous session because it is possible that some switches were easier than others. During reversal learning testing, there were no differences in performance (measured by the total number of trials or proportions of correct, perseverative, or neutral errors) that were related only to the current hole being reinforced (all \(F^2s<1\)). Nevertheless,
ANOVA revealed a main effect of the hole trained in the previous session when considering the percentage of responses that were perseverative \( F(1,80)=11.2, p \leq 0.001 \) and on total number of trials to meet criteria \( F(1,80)=4.1, p \leq 0.05 \); in fact, when the previous hole was internal (i.e., directly adjacent to the hole in which the observing response was made: H2 and H4), subjects made more perseverative responses and took more trials to complete the session. In other words, rats have slightly more difficulty switching away from the internal holes. However, all drug conditions were explicitly balanced to control for the type of reversal sequence being imposed (all drug treatment conditions were evaluated using an equal number of shifts from the internal-to-external and external-to-internal holes).

Experiment 1: differential effects of MPH on the retention and reversal of a four-choice discrimination

Based upon previous studies showing the beneficial effect of MPH on aspects of behavioral inhibition (Aron et al. 2003a; Blondeau and Dellu-Hagedorn 2007; Eagle et al. 2007; Navarra et al. 2008; Tannock et al. 1989), we hypothesized that this drug would improve reversal performance while not affecting retention performance. As shown in Fig. 3a, the two doses of MPH tested differently affected the total number of trials required to reach criteria in the two testing conditions [dose × testing condition: \( F(1,22)=6.1, p \leq 0.01 \); dose: \( F(1,22)=0.4, p = 0.69 \)]. Consistent with our a priori hypothesis, MPH at the dose of 0.33 mg/kg decreased the total number of trials required to complete the reversal session (one-tailed \( t \) test: \( t=1.7, df=22, p \leq 0.05 \)); notably, it increased the total number of trials required to reach criteria in the retention session (two-tailed \( t \) test: \( t=-2.8, df=22, p \leq 0.01 \)). The higher dose of MPH (1 mg/kg), on the other hand, did not significantly affect the total number of trials to criteria in either the reversal (one-tailed \( t \) test: \( t=0.3, df=22, p = 0.39 \)) or retention sessions (two-tailed \( t \) test: \( t=-1.2, df=22, p = 0.24 \)).

Neither dose of MPH affected other measures collected, such as the latency to initiate a trial [dose × testing condition: \( F(1,22)=0.8, p = 0.46 \); dose: \( F(1,22)=1.2, p = 0.29 \)], the pellet retrieval time [dose × testing condition: \( F(1,22)=0.6, p = 0.55 \) dose: \( F(1,22)=0.2, p = 0.81 \)], or the number of anticipatory responses made per trial completed [dose × testing condition: \( F(1,22)=0.3, p = 0.73 \); dose: \( F(1,22)=0.3, p = 0.77 \)] (Table 1).

In order to evaluate the source of these effects of MPH on trials to criteria, we next examined drug effects on the proportion of total trials that were completed correctly and incorrectly in the two learning conditions. For retention performance, ANOVA detected a main effect of dose on correct responding in the first four-five-trial bins [bin × dose: \( F(1,22)=2.4, p \leq 0.05 \); dose: \( F(1,22)=3.2, p \leq 0.05 \)] due to the fact that rats treated with the lower dose of MPH were overall less accurate than after saline administration (Fig. 3b). For the reversal sessions, there was also a significant bin × dose interaction [\( F(1,22)=13.0, p \leq 0.001 \)], without a main effect of dose, for the proportion of trials completed correctly \( [F(1,22)=1.7, p=0.20] \); MPH increased correct responding in the last two five-trial bins (Fig. 3b). Furthermore, no main effect of dose was found for perseverative responding \( [F(1,22)=0.1, p=0.87] \) or for neutral errors \( [F(1,22)=1.4, p=0.26] \), though there was a significant dose × bin interaction for perseverative \( [F(1,22)=2.2, p \leq 0.05 \]) \) (Fig. 3c), but not for neutral errors \( [F(1,22)=0.5, p = 0.87] \) (data not shown). This resulted from
decreased perseveration in the final five-trial bins, an effect specific to the lower dose of MPH (Fig. 3c).

Experiment 2: selective inhibition of the DAT does not affect performance of the four-choice task

For these studies, the same set of rats (n=23) involved in the MPH study were used to evaluate the effects of GBR. As shown in Fig. 4a, the two doses of GBR tested (2.5 and 5 mg/kg) did not affect the total number of trials required to reach criteria in either the retention or reversal sessions [testing condition × dose: F(1,22)=0.2, p=0.82; dose: F(1,22)=1.2, p=0.31]. However, GBR did dose-dependently increase the number of anticipatory responses per trial [dose × testing condition: F(1,22)=1.1, p=0.35; dose: F(1,22)=3.9, p≤0.05]. Post hoc comparisons revealed that the increase in anticipatory responses was significant for the higher dose of GBR in the retention session (t=−2.6, df=22, p=0.05; Table 1). The latency to initiate a trial and the pellet retrieval time were not altered by GBR [dose × testing condition: all Fs<1; dose, respectively: F(1,22)=1.2, p=0.31; F(1,22)=1.3, p=0.075] (Table 1).

In terms of the effect of GBR on the accuracy in the first 20 trials of the retention session, the ANOVA failed to reach significance [dose × bin: F(1,22)=0.1, p=0.99; dose: F(1,22)=2.1, p=0.13] (Fig. 4b). Considering the first five bins of the reversal session, no effect of GBR was found for the proportion of total trials completed correctly [dose × bin: F(1,22)=1.5, p=0.17; dose: F(1,22)=0.1, p=0.88] (Fig. 4b), for perseveration [dose × bin: F(1,22)=0.5, p=0.84; dose: F(1,22)=0.7, p=0.50] (Fig. 4c), or for neutral errors [dose × bin: F(1,22)=1.8, p=0.08; dose: F(1,22)=0.7, p=0.53] (data not shown).

Experiment 3: NET inhibitors selectively improve performance in the reversal sessions

Based upon our preliminary studies using a two-choice task (Seu and Jentsch 2006), we hypothesized that NET inhibitors (ATO and DMI) would improve performance of the four-choice reversal learning task. A priori tests revealed that both ATO and DMI decreased the total number of trials required to reach criteria in the reversal session (ATO: t=1.7, df=21, p=0.05; DMI: t=2.4, df=15, p≤0.05), while neither treatment affected the number of trials to criteria in retention (ATO t=0.8, df=21, p=0.44; DMI: t=−0.51, df=15, p=0.62; Figs. 5a and 6a). The ANOVA failed to detect a significant effect of dose on total trials to criterion for both ATO [F(1,21)=3.3, p=0.08] and DMI [F(1,15)=2.4, p=0.14]; however, there was a significant dose × testing condition interaction for DMI [F(1,15)=6.3, p≤0.05], but not for ATO [F(1,21)=1.3, p=0.27]. As shown in Figs. 5b and 6b, ATO and DMI did not affect correct responding in the first four five-trial bins of the retention sessions (all Fs<1, ns). In addition, ANOVA detected only trends for increases in correct responding in reversal for both NET inhibitors [ATO: F(1,21)=2.7, p=0.12; DMI: F(1,15)=3.3, p=0.09]; however, there was a significant dose × bin interaction for DMI [F(1,15)=2.3, p=0.04], but not for ATO [F(1,21)=1.4, p=0.24] (Figs. 5b and 6b).

Notably, ANOVA detected a main effect of dose for both NET inhibitors on perseverative responses during reversal [ATO: F(1,21)=4.8, p=0.04; DMI: F(1,15)=4.9, p=0.04], as well as a dose × bin interaction for DMI [F(1,15)=2.4, p=0.04], but not for ATO [F(1,21)=1.3, p=0.28] (Figs. 5c and 6c). On the other hand, there was no main effect of dose for

---

### Table 1 Effect of MPH, GBR, ATO, and DMI on motor latencies and anticipatory responding

| Drug | Dose (mg/kg) | Mean trial initiation latency (s) | Mean pellet retrieval time (s) | Tot anticipatory/Tot trials |
|------|-------------|---------------------------------|------------------------------|---------------------------|
|      |             | Retention | Reversal                  | Retention | Reversal                  | Retention | Reversal                  |
| MPH  | 0           | 3.89±0.49 | 4.94±0.68                  | 1.34±0.05 | 1.30±0.03                  | 0.98±0.13 | 0.99±0.11                  |
|      | 0.3         | 4.06±0.46 | 4.29±0.42                  | 1.35±0.04 | 1.26±0.04                  | 1.10±0.17 | 0.98±0.11                  |
|      | 1           | 4.34±0.45 | 4.92±0.48                  | 1.34±0.05 | 1.30±0.03                  | 1.05±0.14 | 0.93±0.11                  |
| GBR  | 0           | 3.58±0.52 | 3.74±0.35                  | 1.36±0.05 | 1.28±0.04                  | 0.71±0.13 | 0.78±0.08                  |
|      | 2.5         | 3.69±0.32 | 3.31±0.29                  | 1.36±0.06 | 1.30±0.03                  | 0.96±0.16 | 0.88±0.12                  |
|      | 5           | 3.47±0.40 | 3.05±0.26                  | 1.33±0.05 | 1.29±0.04                  | 1.19±0.24 | 0.95±0.12                  |
| ATO  | 0           | 4.52±0.53 | 4.14±0.41                  | 1.41±0.05 | 1.36±0.04                  | 1.08±0.15 | 1.26±0.13                  |
|      | 1           | 4.73±0.56 | 5.29±0.67                  | 1.44±0.05 | 1.46±0.05*                  | 1.04±0.13 | 0.96±0.11                  |
| DSI  | 0           | 5.70±1.08 | 7.47±1.90                  | 1.52±0.09 | 1.44±0.08                  | 1.25±0.29 | 0.90±0.12                  |
|      | 1           | 8.50±1.89*| 9.56±1.45                  | 1.67±0.13*| 1.60±0.09**                  | 0.87±0.16 | 0.75±0.12                  |

Mean trial initiation latency, mean pellet retrieval time, and number of anticipatory response per trial, under retention or reversal condition, are reported for all pharmacological studies. Trial initiation latency and pellet retrieval time are expressed as mean (in s) of total time ±SEM; anticipatory responses are expressed as the mean of responses/trials completed ±SEM.

*p≤0.05, significantly different from saline; **p≤0.01
either of the two drugs on neutral errors [ATO: \(F_{(1,21)}=0.04, p=0.85\); DMI: \(F_{(1,15)}=0.06, p=0.81\)] (data not shown) nor were there any dose × testing condition interactions [ATO: \(F_{(1,21)}=1.5, p=0.21\); DMI: \(F_{(1,15)}=0.9, p=0.50\)].

As shown in Table 1, the latency to initiate a trial tended to be affected by ATO [dose × testing condition: \(F_{(1,21)}=1.6, p=0.22\); dose: \(F_{(1,21)}=3.1, p=0.09\)], while for DMI, there was a main effect of dose \([F_{(1,15)}=5.2, p\leq0.05]\) but no dose × testing condition interaction \([F_{(1,15)}=0.1, p=0.78]\); further paired comparisons revealed that DMI significantly increased latency only in the retention sessions \((t=-2.1, df=15, p\leq0.05;\) Table 1). In addition, the time required to retrieve the reward was affected by both ATO [dose × testing condition: \(F_{(1,21)}=2.8, p=0.11\); dose: \(F_{(1,21)}=4.3, p\leq0.05\)] and DMI [dose × testing condition: \(F_{(1,15)}=0.0, p=0.95\); dose: \(F_{(1,15)}=18.2, p\leq0.001\)]. As shown in Table 1, ATO increased pellet retrieval time in the reversal sessions \((t=-2.5, df=21, p\leq0.05)\), while DMI exerted effects in both the retention \((t=-2.2, df=15, p\leq0.05)\) and the reversal sessions \((t=-3.4, df=15, p\leq0.01)\). Anticipatory responses were not affected by ATO [dose × testing condition: \(F_{(1,21)}=1.4, p=0.24\); dose: \(F_{(1,21)}=1.9, p=0.17\)], while there was a trend for a main effect of dose for DMI \([F_{(1,15)}=3.9, p=0.06]\) without a significant dose × testing condition interaction \([F_{(1,15)}=0.9, p=0.36]\) (Table 1).

Monkey studies: effect of MPH and ATO on performance of a visual discrimination task

The effect of MPH and ATO was also tested in non-human primates performing a visual discrimination task. Considering the retention session (data not shown), there was no main effect of drug treatment for the total number of errors \([F_{(2,6)}=1.5, p=0.3]\). ATO did not alter the total
subjects when reversing the discrimination that was preceded by a retention test (one-tailed t test: $t=2.4$, $df=3$, $p\leq0.05$; Fig. 7) while not affecting perseveration for the reversal which was not preceded by a retention test (one-tailed t test: $t=-0.5$, $df=3$, $p=0.69$; data not shown). The opposite trend was observed for MPH; the drug did not significantly affect reversal of the discrimination that was preceded by a retention test (one-tailed t test: $t=1.2$, $df=3$, $p=0.15$; Fig. 7) but tended to decrease perseverative errors when the non-retained discrimination was reversed (one-tailed t test: $t=1.9$, $df=3$, $p=0.07$; data not shown). Neither of the drugs tested affected the number of neutral errors made when reversal followed retention [effect of treatment: $F_{(2,6)}=1.2$, $p=0.4$; two-tailed t tests, ATO: $t=-1.2$, $df=3$, $p=0.31$; MPH: $t=1.0$, $df=3$, $p=0.36$ (Fig. 7) or when it did not [effect of treatment: $F_{(2,6)}=0.9$, $p=0.5$; two-tailed t tests, ATO: $t=1.2$, $df=3$, $p=0.28$; MPH: $t=-1.2$, $df=3$, $p=0.30$] (data not shown).

Discussion

Using a novel four-choice position discrimination task developed to study behavioral flexibility in rats, we show that three drugs that inhibit NET with varying degrees of selectivity—ATO, DMI, and MPH—exerted a common effect to reduce the total number of trials required to reverse a learned discrimination; selective inhibition of DAT was not associated with a similar performance effect. Furthermore, very similar effects of ATO and MPH were found in monkeys trained to perform a visual discrimination reversal task.

In the four-choice discrimination task for rats, subjects were required to either retain or reverse a position–reward association learnt in the previous session; the difficulty

number of errors in the retention sessions (two-tailed t test: $t=-0.8$, $df=3$, $p=0.47$), while MPH exerted a very weak trend to increase the total number of errors (two-tailed t test: $t=-1.8$, $df=3$, $p=0.16$). Furthermore, none of the drugs affected the number of errors made during the retention component given within the reversal sessions [ANOVA for effect of treatment: $F_{(2,6)}=2.3$, $p=0.4$; two-tailed t tests, ATO: $t=-0.7$, $df=3$, $p=0.49$; MPH: $t=-1.2$, $df=3$, $p=0.29$] (Fig. 7).

On the other hand, there was a main effect of drug treatment for perseverative errors when reversal was not preceded by retention [between session reversal; main effect of drug: $F_{(2,6)}=5.4$, $p=0.04$], while the effect of treatment on perseverative errors preceded by retention was at a trend level [within session reversal; $F_{(2,6)}=3.8$, $p=0.08$]. Tests of a priori hypotheses showed that ATO decreased the number of perseverative errors made by

![Fig. 6](image_url)  
Effect of DMI (5 mg/kg) or SAL (1 ml/kg) on a total number of trials to criteria, b on correct, and c perseverative responses (% of total responses). Data are expressed as mean±SEM ($n=16$). *$p\leq0.05$, significantly different from saline; **$p\leq0.01$; ***$p\leq0.001$

![Fig. 7](image_url)  
Effect of MPH (0.33 mg/kg) or ATO (1 mg/kg) on performance on the retention or reversal of discrimination set 2 (i.e., set of discriminanda that were reversed after a priming retention). For the retention phase, we report total number of errors, while for the reversal phase, perseverative and neutral errors are presented separately. Data are expressed as mean of errors±SEM ($n=4$). *$p\leq0.05$, significantly different from saline
associated with switching responses was revealed by the significantly higher number of trials required to complete reversal, as opposed to retention, conditions. The dissociations between retention and reversal performance specifically arose from the conditioned tendency to respond to the previously learnt rule; this pre-potent response style facilitates efficient performance when the rule is unaltered (retention), while it causes difficulty with switching position–reward associations (reversal). Notably, rats appeared to guide their performance according to a set of long-term reinforcement rules that incorporated information learned over many sessions because they responded most to the hole reinforced in the most recent session and least to the hole reinforced longest in the past (Fig. 2b). In addition, reversal of a learned discrimination in monkeys was associated with a specific persistence of responding towards the previously trained stimulus. Taken together, these data support the notion that our tasks incorporate an interesting element of reversal performance which is the need to inhibit a previously learned response.

Behavioral basis of NET inhibitor effects on reversal learning

Further evidence that the reversal tasks used measure the ability to inhibit pre-potent responses stems from the pharmacological studies. In rats, selective NET inhibitors specifically reduced the total number of trials required to complete reversal sessions and tended to increase the proportion of trials completed correctly in the first stages of the session while having no measured effect on performance in retention. Importantly, the effect of NET inhibitors on total trials required to complete the reversal session was associated with a specific decrease in the perseverative responding in the first stage of the session. In monkeys, ATO specifically decreased perseverative responses when the subjects were tested for their ability to change a response after retention (a condition that likely “primes” the conditioned action); this was contrasted with the effect of MPH which only decreased perseverative errors when no retention was given prior to reversal, an effect that may relate to the ability of MPH to disrupt retention and, hence, reduce interference from the previously learned association. These data may suggest that the effects of the NET inhibitors were mediated by increased ability to overcome pre-potent responding toward the previously trained response. Nevertheless, we cannot rule out the possibility that these drugs were improving the ability to overcome learned irrelevance; in both cases, a similar reduction in perseverative responses would be expected.

On the other hand, the selective DAT inhibitor GBR failed to affect retention or reversal performance other than producing a dose-dependent increase in anticipatory responses. Accordingly, previous experiments have shown that the same doses of GBR used in our study increased premature responses in the five-choice serial reaction time task (van Gaalen et al. 2006a) and impulsive decision making in a delayed reward task (van Gaalen et al. 2006b). Together with our results, this evidence suggests that the inhibition of DAT may result in disinhibited responding without affecting other forms of impulsivity such as perseveration; this is in line with the idea that different neuronal mechanisms may underlie different forms of impulsivity (Dalley et al. 2008; Evenden 1999).

The ability of ATO and DMI to improve reversal performance was also displayed by the lower dose (0.33 mg/kg) of the stimulant drug MPH, which is known to inhibit both NET and DAT (Bymaster et al. 2002; Han and Gu 2006). Interestingly, similar doses of MPH have been shown to improve response inhibition (Eagle et al. 2007) and other executive functions in rodents (Amsten and Dudley 2005; Berridge et al. 2006). Collectively, this dose range is associated with plasma concentrations very similar to those produced by clinical dosing in humans. Although the improvement in reversal learning induced by MPH in rats and monkeys was associated with a decrease in perseverative responses, the same dose of MPH was found to generally negatively affect retention performance, an effect not found with selective NET inhibitors. While the improvement in reversal and impairment in retention caused by MPH could, theoretically, be attributed to a deficit in the retrieval of the previously learned rule, making it easier to learn a new response in reversal, this seems not to be the case in the current study because, in rats, methylphenidate reduced perseveration only in the last bins considered (trials 16–25), while one could expect the effect to occur from the first trials if a deficit in rule retrieval was the cause.

Another possible explanation for the opposite effects of MPH on retention and reversal is that the drug generally increases switching behavior; in fact, it has been shown that stimulant drugs increase switching behavior in rodents (Evenden and Robbins 1983). If this effect alone explained the results, however, we might have expected to observe an increase in neutral errors, but this was not the case in the current study.

In contrast to the effects of the 0.33-mg/kg dose, no difference in performance of either testing condition was induced by the high dose of MPH. This may result from an inverted-U dose–response for methylphenidate on cognition such that low dose of this stimulant improves cognitive control, while higher doses induce hyperactivity and cognitive impairment (Berridge et al. 2006; Eagle et al. 2007). In this study, however, the highest dose of MPH did not produce any impairment, disinhibited responding, or...
hyperactivity, suggesting that an inverted-U dose–response effect cannot solely account for our results.

Monoamine systems and behavioral flexibility

Recent data using neurochemical depletion or pharmacological approaches have highlighted a role for the serotonergic system as an important modulator of reversal learning (Boulougouris et al. 2008; Clarke et al. 2007). Our results, along with other experimental and clinical evidence (see below), suggest that the dopaminergic and noradrenergic systems may also contribute to behavioral flexibility and cognitive control. For example, pharmacological or genetic interventions targeting different dopamine receptor subtypes affect performance in reversal learning or attention set-shifting paradigms (Floresco et al. 2006; Izquierdo et al. 2006; Lee et al. 2007; Mehta et al. 2001; Ragozzino 2002). Additionally, administration of the alpha-2 adrenergic receptor agonist guanfacine has been shown to improve reversal learning in aged monkeys (Steere and Arnsten 1997), while in rodents, stimulus reversals and extra-dimensional shift were improved by high dose of the alpha-2 antagonist atipamezole (Lapiz and Morilak 2006). Furthermore, accumulating evidence suggests that dysfunctions of both the noradrenergic and the dopaminergic system may contribute to ADHD symptoms, including impulsivity, inattention, executive dysfunction, and poor cognitive control and that drugs acting on these systems may be helpful for the treatment of the disorder (Arnsten 2006; Biederman and Spencer 1999; Frank et al. 2007; Robbins 2007).

Interestingly, the current study shows that NET inhibitors with clinical efficacy in the treatment of ADHD improve the ability of monkeys and rats to overcome pre-potent responding. Our results are in accord with recent studies reporting the beneficial effects of selective and non-selective NET inhibitors on behavioral inhibition in rodents, healthy humans, and ADHD subjects (Aron et al. 2003a; Blondeau and Delli-Hagedorn 2007; Chamberlain et al. 2007, 2006; Eagle et al. 2007; Navarra et al. 2008; Robinson et al. 2008).

Pharmacological and neurochemical mechanisms

NET and DAT are expressed on noradrenergic and dopaminergic terminals, respectively, and their function is to reuptake norepinephrine or dopamine released in the extracellular compartment in order to terminate their synaptic or extra-synaptic actions; therefore, blockade of NET or DAT results in an increase of extracellular levels of norepinephrine and dopamine, respectively, and consequent stimulation of receptors in brain regions receiving projections from these neurotransmitter systems.

The benefit associated with administration of NET inhibitors, compared with the absence of relevant effects of the selective DAT inhibitor, seems to suggest that the modulation of the noradrenergic system is crucial for the improvement in behavioral flexibility observed in our study. However, it is well known that the selective NET inhibitors are also capable of increasing extracellular dopamine in specific regions such as the prefrontal cortex (Berridge et al. 2006; Bymaster et al. 2002; Swanson et al. 2006). In fact, in the prefrontal cortex, a low expression of DAT (Lammel et al. 2008) indicates that a significant portion of extracellular dopamine is cleared by NET (Carboni et al. 2006; Mazié et al. 2002; Moron et al. 2006) which has high affinity for both catecholamines. For this reason, administration of selective and non-selective NET inhibitors results in increase of both norepinephrine and dopamine within the prefrontal cortex (Berridge et al. 2006; Bymaster et al. 2002; Swanson et al. 2006), while local infusion of selective DAT inhibitors does not significantly affect extracellular levels of dopamine in the cortex (Mazié et al. 2002). On the other hand, drugs acting on DAT, including MPH, increase dopamine in the ventral and dorsal striatum (Carboni et al. 2006; Kuczenski and Segal 1997), an action that is not displayed by selective NET inhibitors (Bymaster et al. 2002), and these neurochemical effects have been related to the abuse liability of stimulants medications. For these reasons, the modulation of extracellular levels of both catecholamines in specific regions such as the prefrontal or orbitofrontal cortex may be the mechanism by which NET inhibitors improve inhibitory control and behavioral flexibility.

Conclusion

Conceptually, treatments that enhance executive/cognitive control over pre-potent responses are emerging as leading candidate medications for the treatment of an array externalizing disorders, including ADHD, substance abuse and dependence, and other forms of impulse control problems. The extent to which selective inhibitors of the norepinephrine membrane transporter improve multiple aspects of inhibitory control over responding (Blondeau and Delli-Hagedorn 2007; Chamberlain et al. 2007; Lapiz et al. 2007; Navarra et al. 2008; Robinson et al. 2008) underscores their potential in regards to the treatment of these behavioral disorders. What remain unknown, however, are the discrete neuronal effects of increased extracellular dopamine and norepinephrine levels that contribute to these enhancements in inhibitory control. While certain component processes that contribute to cognitive control, e.g., working memory maintenance, depend more on dopamine D1-like receptor signaling (Arnsten et al. 1994;
Sawaguchi and Goldman-Rakic 1991), recent work also indicates that D2-like signaling likely plays an important role in updating central representations and behavior (Floresco et al. 2006; Lee et al. 2007; Wang et al. 2004), demonstrating the complex mechanisms by which catecholamine transmitters modulate dissociable aspects of cognitive and executive functioning. Further work exploring these multifaceted effects of catecholamine transmitters is clearly needed.

Acknowledgment These experiments were funded, in part, by PHS grants P50-MH77248 and P20-DA22539 to JDJ, as well as a grant from the Tenenbaum Creativity Initiative at UCLA.

Conflicts of interest The authors have no competing conflicts of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

Armsten AF (2006) Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways. J Clin Psychiatry 67(Suppl 8):7–12
Armsten AF, Dudley AG (2005) Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: relevance to therapeutic effects in attention deficit hyperactivity disorder. Behav Brain Funct 1:2
Armsten AF, Li BM (2005) Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol Psychiatry 57:1377–1384
Armsten AF, Cai JX, Murphy BL, Goldman-Rakic PS (1994) Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology (Berl) 116:143–151
Aron AR, Dowson JH, Sahakian BJ, Robbins TW (2003a) Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 54:1465–1468
Aron AR, Fletcher PC, Bullmore ET, Sahakian BJ, Robbins TW (2003b) Stop-signal inhibition disrupted by damage to right inferior frontal gyrus in humans. Nat Neurosci 6:115–116
Berridge CW, Devilbiss DM, Andrzejewski ME, Amsten AF, Kelley AE, Schmeichel B, Hamilton C, Spencer RC (2006) Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry 60:1111–1120
Biederman J, Spencer T (1999) Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 46:1234–1242
Birrell JM, Brown VJ (2000) Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 20:4320–4324
Blondeau C, Della-Hagedorn F (2007) Dimensional analysis of ADHD subtypes in rats. Biol Psychiatry 61:1340–1350
Boulougouris V, Dalley JW, Robbins TW (2007) Effects of orbitofrontal, infralimbic and prelimbic cortical lesions on serial spatial reversal learning in the rat. Behav Brain Res 179:219–228
Boulougouris V, Glennon JC, Robbins TW (2008) Dissociable effects of selective 5-HT2A and 5-HT2C receptor antagonists on serial spatial reversal learning in rats. Neuropsychopharmacology 33:2007–2019
Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW (2002)Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699–711
Cali DJ, Stalnaker TA, Franz TM, Singh T, Shaham Y, Schoenbaum G (2007) Withdrawal from cocaine self-administration produces long-lasting deficits in orbitofrontal-dependent reversal learning in rats. Learn Mem 14:325–328
Carboni E, Silvagni A, Vacca C, Di Chiara G (2006) Cumulative effect of norepinephrine and dopamine carrier blockade on extracellular dopamine increase in the nucleus accumbens shell, bed nucleus of stria terminalis and prefrontal cortex. J Neurochem 96:473–481
Chamberlain SR, Muller U, Blackwell AD, Clark L, Robbins TW, Sahakian BJ (2006) Neurochemical modulation of response inhibition and probabilistic learning in humans. Science 311:861–863
Chamberlain SR, Del Campo N, Dowson J, Muller U, Clark L, Robbins TW, Sahakian BJ (2007) Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biol Psychiatry 62:977–984
Clarke HE, Walker SC, Dalley JW, Robbins TW, Roberts AC (2007) Cognitive inflexibility after prefrontal serotonin depletion is behaviorally and neurochemically specific. Cereb Cortex 17:18–27
Dalley JW, Mar AC, Economoudou D, Robbins TW (2008) Neurobehavioral mechanisms of impulsivity: fronto-striatal systems and functional neurochemistry. Pharmacol Biochem Behav 90:250–260
Dias R, Robbins TW, Roberts AC (1996) Dissociation in prefrontal cortex of affective and attentional shifts. Nature 380:69–72
Eagle DM, Tufti MR, Goodchild HL, Robbins TW (2007) Differential effects of modafinil and methylphenidate on stop-signal reaction time task performance in the rat, and interactions with the dopamine receptor antagonist cis-flupenthixol. Psychopharmacology (Berl) 192:193–206
Eagle DM, Baunez C, Hutcheson DM, Lehmann O, Shah AP, Robbins TW (2008) Stop-signal reaction-time task performance: role of prefrontal cortex and subthalamic nucleus. Cereb Cortex 18:178–188
Evenden JL (1999) Varieties of impulsivity. Psychopharmacology (Berl) 146:348–361
Evenden JL, Robbins TW (1983) Increased response switching, perseveration and perseverative switching following d-amphetamine in the rat. Psychopharmacology (Berl) 80:67–73
Everitt B, Hutcheson DM, Erseke KD, Everitt Y, Dalley J, Robbins TW (2007) The orbital frontal cortex and drug addiction in animals and humans. Ann N Y Acad Sci 1121:576–597
Fanone SV, Biederman J, Spencer T, Michelson D, Adler L, Reinherr F, Glatt SJ (2005) Efficacy of atomoxetine in adult attention-deficit/hyperactivity disorder: a drug-placebo response curve analysis. Behav Brain Funct 1:16
Fillmore MT, Rush CR (2002) Impaired inhibitory control of behavior in chronic cocaine users. Drug Alcohol Depend 66:265–273
Fillmore MT, Rush CR (2006) Polydrug abusers display impaired discrimination-reversal learning in a model of behavioural control. J Psychopharmacol 20:24–32
Floresco SB, Magyar O, Ghods-Sharifi S, Vexelman C, Tse MT (2006) Multiple dopamine receptor subtypes in the medial prefrontal cortex of the rat regulate set-shifting. Neuropsychopharmacology 31:297–309
Frank MJ, Claus ED (2006) Anatomy of a decision: striato-orbitofrontal interactions in reinforcement learning, decision making, and reversal. Psychol Rev 113:300–326
Frank MJ, Santamaria A, O'Reilly RC, Willcutt E (2007) Testing computational models of dopamine and noradrenaline dysfunction in attention deficit/hyperactivity disorder. Neuropsychopharmacology 32:1583–1599
Han DD, Gu HH (2006) Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 6:6
Hesslinger B, Tebartz van Est L, Thié T, Haegele K, Hennig J, Ebert D (2002) Frontoorbital volume reductions in adult patients with attention deficit hyperactivity disorder. Neurosci Lett 328:319–321
Hornak J, O'Doherty J, Bramham J, Rolls ET, Morris RG, Bullock PR, Polkey CE (2004) Reward-reward reversal learning after surgical excisions in orbito-frontal or dorsolateral prefrontal cortex in humans. J Cogn Neurosci 16:463–478
Itami S, Uno H (2002) Orbitofrontal cortex dysfunction in attention-deficit hyperactivity disorder revealed by reversal and extinction tasks. Neuroreport 13:2453–2457
Iversen SD, Mishkin M (1970) Perseverative interference in monkeys following selective lesions of the inferior prefrontal convexity. Exp Brain Res 11:376–386
Izquierdo A, Wiedholz LM, Milstein RA, Yang RJ, Bussey TJ, Sakaida LM, Holmes A (2006) Genetic and dopaminergic modulation of reversal learning in a touchscreen-based operant procedure for mice. Behav Brain Res 171:181–198
Jentsch JD (2003) Genetic vasopressin deficiency facilitates performance of a lateralized reaction-time task: altered attention and motor processes. J Neurosci 23:1066–1071
Jentsch JD, Olausson P, De La Garza R 2nd, Taylor JR (2002) Impairments of reversal learning and response perseveration after repeated, intermittent cocaine administrations to monkeys. Neuropsychopharmacology 26:183–190
Kuczenski R, Segal DS (1997) Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 68:2032–2037
Lammel MD, Morilak DA (2006) Noradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional set shifting capability. Neuroscience 137:1039–1049
Lapiz MD, Bondi CO, Morilak DA (2007) Chronic treatment with desipramine improves cognitive performance of rats in an attentional set-shifting test. Neuropsychopharmacology 32:1000–1010
Lee B, Groman S, London ED, Jentsch JD (2007) Dopamine D2/D3 receptors play a specific role in the reversal of a learned visual discrimination in monkeys. Neuropsychopharmacology 32:2125–2134
Mazei MS, Pluto CP, Kirkbride B, Pehek EA (2002) Effects of catecholamine uptake blockers in the caudate-putamen and subregions of the medial prefrontal cortex of the rat. Brain Res 936:58–67
McAlonan K, Brown VJ (2003) Orbital prefrontal cortex mediates reversal learning and not attentional set shifting in the rat. Behav Brain Res 146:97–103
Mehta MA, Swainson R, Ogilvie AD, Sahakian J, Robbins TW (2001) Improved short-term spatial memory but impaired reversal learning following the dopamine D2 agonist bromocriptine in human volunteers. Psychopharmacology (Berl) 159:10–20
Miller EK, Cohen JD (2001) An integrative theory of prefrontal cortex function. Annu Rev Neurosci 24:167–202
Monterosso JR, Aron AR, Cordova X, Xu J, London ED (2005) Deficits in response inhibition associated with chronic methamphetamine abuse. Drug Alcohol Depend 79:273–277
Moron JA, Brockington A, Wise RA, Rocha BA, Hope BT (2002) Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 22:389–395
Navarra R, Graf R, Huang Y, Logue S, Comery T, Hughes Z, Day M (2008) Effects of atomoxetine and methylphenidate on attention and impulsivity in the 5-choice serial reaction time test. Prog Neuropsychopharmacol Biol Psychiatry 32:34–41
Olausson P, Jentsch D, Krueger DD, Tronson N, Nairn AC, Taylor JR (2007) Orbitofrontal cortex and cognitive-motivational impairments in psychostimulant addiction: evidence from experiments in the non-human primate. Ann N Y Acad Sci 1121:610–638
Owen AM, Roberts AC, Polkey CE, Sahakian BJ, Robbins TW (1991) Extra-dimensional versus intra-dimensional set shifting performance following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man. Neuropsychologia 29:993–1006
Ragozzino ME (2002) The effects of dopamine D1 receptor blockade in the prelimbic-infralimbic areas on behavioral flexibility. Learn Mem 9:18–28
Ragozzino M (2007) The contribution of the medial prefrontal cortex, orbitofrontal cortex and dorsolateral striatum to behavioral flexibility. Ann N Y Acad Sci 1121:355–375
Ragozzino ME, Kesner RP (2001) The role of rat dorsomedial prefrontal cortex in working memory for egocentric responses. Neurosci Lett 308:145–148
Robbins TW (2005) Chemistry of the mind: neurochemical modulation of prefrontal cortical function. J Comp Neurol 493:140–146
Robbins TW (2007) Shifting and stopping: fronto-striatal substrates, neurochemical modulation and clinical implications. Philos Trans R Soc Lond B Biol Sci 362:917–932
Roberts AC, Wallis JD (2000) Inhibitory control and affective processing in the prefrontal cortex: neuropsychological studies in the common marmoset. Cereb Cortex 10:252–262
Robinson ES, Eagle DM, Mar AC, Bari A, Banerjee G, Jiang X, Dalley JW, Robbins TW (2008) Similar effects of the selective noradrenaline reuptake inhibitor atomoxetine on three distinct forms of impulsivity in the rat. Neuropsychopharmacology 33:1028–1037
Rolls ET, Hornak J, Wade D, McGrath J (1994) Emotion-related learning in patients with social and emotional changes associated with frontal lobe damage. J Neurol Neurosurg Psychiatry 57:1518–1524
Savaguchi T, Goldman-Rakic PS (1991) D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 251:947–950
Schachar R, Tannock R, Marriott M, Logan G (1995) Deficient inhibitory control in attention deficit hyperactivity disorder. J Abnorm Child Psychol 23:411–437
Schachar R, Mota VL, Logan GD, Tannock R, Klim P (2000) Confirmation of an inhibitory control deficit in attention-deficit/hyperactivity disorder. J Abnorm Child Psychol 28:227–235
Scheres A, Oosterlaan J, Swanson J, Morein-Zamir S, Meiran N, Schut H, Vlasveld L, Sergeant JA (2003) The effect of methylphenidate on three forms of response inhibition in boys with ADHD. J Abnorm Child Psychol 31:105–120
Schoenbaum G, Shaham Y (2008) The role of orbitofrontal cortex in drug addiction: a review of preclinical studies. Biol Psychiatry 63:256–262
Schoenbaum G, Nugent SL, Saddoris MP, Setlow B (2002) Orbitofrontal lesions in rats impair reversal but not acquisition of go, no-go odor discriminations. Neuroreport 13:885–890
Seu E, Jentsch JD (2006) Alpha-2A noradrenergic mechanisms modulate the acquisition and reversal of a position discrimination task in rats. Soc Neurosci Abstr 571:17

Spencer T, Biederman J, Heiligenstein J, Wilens T, Faries D, Prince J, Faraone SV, Rea J, Witcher J, Zervas S (2001) An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 11:251–265

Steere JC, Arnsten AF (1997) The alpha-2A noradrenergic receptor agonist guanfacine improves visual object discrimination reversal performance in aged rhesus monkeys. Behav Neurosci 11:833–891

Swanson CJ, Perry KW, Koch-Krueger S, Katner J, Svensson KA, Bymaster FP (2006) Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology 50:755–760

Tait DS, Brown VJ (2007) Difficulty overcoming learned non-reward during reversal learning in rats with ibotenic acid lesions of orbital prefrontal cortex. Ann N Y Acad Sci 1121:407–420

Tannock R, Schachar RJ, Carr RP, Chajczyk D, Logan GD (1989) Effects of methylphenidate on inhibitory control in hyperactive children. J Abnorm Child Psychol 17:473–491

van Gaalen MM, Brueggeman RJ, Bronius PF, Schoffelmeer AN, Vanderschuren LJ (2006a) Behavioral disinhibition requires dopamine receptor activation. Psychopharmacology (Berl) 187:73–85

van Gaalen MM, van Koten R, Schoffelmeer AN, Vanderschuren LJ (2006b) Critical involvement of dopaminergic neurotransmission in impulsive decision making. Biol Psychiatry 60:66–73

Volkow ND, Swanson JM (2003) Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 160:1909–1918

Wang M, Vijayraghavan S, Goldman-Rakic PS (2004) Selective D2 receptor actions on the functional circuitry of working memory. Science 303:853–856

Willcutt EG, Doyle AE, Nigg JT, Faraone SV, Pennington BF (2005) Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review. Biol Psychiatry 57:1336–1346